Autopsy report · NCT01716039

Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)

“Unable to achieve recruitment target.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 8 months before it started.
• Ran for about 3 years 1 month before it stopped.
• 22 participants enrolled.
• Results were posted on the registry 4 years 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Alimentiv Inc.

Sponsor type

University, hospital or other

Conditions

Ulcerative Colitis

Interventions

MTX 12.5; MTX 25; Adalimumab

Participants

22

Trials that died the same way

• Identification of Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis
  “Not able to meet recruitment targets” (84% match in meaning)
• Evaluation of the Versamed iVent in the Transport of Patients Receiving Mechanical Ventilation
  “Unable to recruit adequately” (80% match in meaning)
• Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway
  “Target recruitment not reached” (79% match in meaning)
• A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal
  “Unable to meet the study's recruitment goals” (79% match in meaning)
• Efficacy and Safety of Hemorrane Plus Versus Hemorrane and Versus Placebo in Patients With Uncomplicated Haemorrhoids
  “Recruitment failure” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.